Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Renal Insufficiency 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Hematologic Diseases 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 16Dexamethasone 14Melphalan 12Bortezomib 11Filgrastim 6Peripheral Blood Stem Cell Transplantation 5Lenalidomide 5Thalidomide 4Prednisone 4sargramostim 3fludarabine phosphate 3daratumumab 3Radiotherapy 3Mycophenolic Acid 3Interferon-alpha 3Doxorubicin 3Busulfan 3Antilymphocyte Serum 3pomalidomide 2isatuximab 2fludarabine 2Vincristine 2Methylprednisolone 2Idarubicin 2Cyclosporine 2Carmustine 2plerixafor 1pegfilgrastim 1orantinib 1epoetin beta 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasms, Plasma Cell × Ranitidine × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡